Diabetes Leadership Edge: The Convergence of Cardiovascular Risk Reduction and Glucose Management in Patients with Type 2 Diabetes Supplement

This is a supplement to the January 2019 JAAPA and explores the relationship between type 2 Diabetes (T2D) and cardiovascular disease and is part of AAPA’s curriculum known as Diabetes Leadership Edge.

Educational Objectives
At the conclusion of this activity, participants should be able to:
  • Describe the mechanisms by which type 2 diabetes contributes to cardiovascular disease.
  • Critically appraise the results of cardiovascular outcomes trials of glucose-lowering drugs.
  • Differentiate glucose-lowering drugs with regard to cardiovascular effects.
  • Select glucose-lowering strategies for patients in the context of the patient’s overall cardiovascular risk profile.